Differential protein expression profiles in estrogen receptor-positive and -negative breast cancer tissues using label-free quantitative proteomics.

Identification of the proteins that are associated with estrogen receptor (ER) status is a first step towards better understanding of the hormone-dependent nature of breast carcinogenesis. Although a number of gene expression analyses have been conducted, protein complement has not been systematically investigated to date. Because proteins are primary targets of therapeutic drugs, in this study, we have attempted to identify proteomic signatures that demarcate ER-positive and -negative breast cancers. Using highly enriched breast tumor cells, replicate analyses from 3 ERα+ and 3 ERα- human breast tumors resulted in the identification of 2,995 unique proteins with ≥2 peptides. Among these, a number of receptor tyrosine kinases and intracellular kinases that are abundantly expressed in ERα+ and ERα- breast cancer tissues were identified. Further, label-free quantitative proteome analysis revealed that 236 proteins were differentially expressed in ERα+ and ERα- breast tumors. Among these, 141 proteins were selectively up-regulated in ERα+, and 95 proteins were selectively up-regulated in ERα- breast tumors. Comparison of differentially expressed proteins with a breast cancer database revealed 98 among these have been previously reported to be involved in breast cancer. By Gene Ontology molecular function, dehydrogenase, reductase, cytoskeletal proteins, extracellular matrix, hydrolase, and lyase categories were significantly enriched in ERα+, whereas selected calcium-binding protein, membrane traffic protein, and cytoskeletal protein were enriched in ERα- breast tumors. Biological process and pathway analysis revealed that up-regulated proteins of ERα+ were overrepresented by proteins involved in amino acid metabolism, proteasome, and fatty acid metabolism, while up-regulated proteins of ERα- were overrepresented by proteins involved in glycolysis pathway. The presence and relative abundance of 4 selected differentially abundant proteins (liprin-α1, fascin, DAP5, and β-arrestin-1) were quantified and validated by immunohistochemistry. In conclusion, unlike in vitro cell culture models, the in vivo signaling proteins and pathways that we have identified directly from human breast cancer tissues may serve as relevant therapeutic targets for the pharmacological intervention of breast cancer.

[1]  J. Seilhamer,et al.  A comparison of selected mRNA and protein abundances in human liver , 1997, Electrophoresis.

[2]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[3]  Linfeng Wu,et al.  A Systematic Characterization of Mitochondrial Proteome from Human T Leukemia Cells*S , 2005, Molecular & Cellular Proteomics.

[4]  中尾 光輝,et al.  KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース) , 2000 .

[5]  L. Yamamoto,et al.  Estrogen and progesterone receptor mrna levels in primary breast cancer: Association with patient survival and other clinical and tumor features , 1994, International journal of cancer.

[6]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[7]  E. Falkenstein,et al.  Nongenomic steroid action: controversies, questions, and answers. , 2003, Physiological reviews.

[8]  N. S. Mcnutt,et al.  Differential expression of the intermediate filament peripherin in cutaneous neural lesions and neurotized melanocytic nevi. , 1997, The American journal of surgical pathology.

[9]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[10]  C. Osborne,et al.  Steroid hormone receptors in breast cancer management , 2004, Breast Cancer Research and Treatment.

[11]  U. Pastorino,et al.  Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids. , 2003, Lung cancer.

[12]  A. Debant,et al.  The LAR transmembrane protein tyrosine phosphatase and a coiled‐coil LAR‐interacting protein co‐localize at focal adhesions. , 1995, The EMBO journal.

[13]  N. Goto,et al.  Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma , 2003, Cancer Chemotherapy and Pharmacology.

[14]  J. Jones,et al.  A review of the S100 proteins in cancer. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  C. Schneeberger,et al.  Production and actions of estrogens. , 2002, The New England journal of medicine.

[16]  S. Weed,et al.  Cortactin: coupling membrane dynamics to cortical actin assembly , 2001, Oncogene.

[17]  A. Mobasheri,et al.  Hypoxic Regulation of Glucose Transport, Anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer Therapeutics , 2007, Chemotherapy.

[18]  S. Fuqua,et al.  The role of the estrogen receptor in tumor progression , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  J. Ross,et al.  Actin‐binding protein fascin expression in skin neoplasia , 2002, Journal of cutaneous pathology.

[20]  K. Korach,et al.  The Multifaceted Mechanisms of Estradiol and Estrogen Receptor Signaling* , 2001, The Journal of Biological Chemistry.

[21]  E. Schuuring,et al.  Comparative genome analysis of cortactin and HS1: the significance of the F-actin binding repeat domain , 2005, BMC Genomics.

[22]  O. Larsson,et al.  β-Arrestin Is Crucial for Ubiquitination and Down-regulation of the Insulin-like Growth Factor-1 Receptor by Acting as Adaptor for the MDM2 E3 Ligase* , 2005, Journal of Biological Chemistry.

[23]  R. Higgs,et al.  Proteomics: from hypothesis to quantitative assay on a single platform. Guidelines for developing MRM assays using ion trap mass spectrometers. , 2008, Briefings in functional genomics & proteomics.

[24]  R A Jungmann,et al.  c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  N. Goto,et al.  WF‐536 INHIBITS METASTATIC INVASION BY ENHANCING THE HOST CELL BARRIER and INHIBITING TUMOUR CELL MOTILITY , 2003, Clinical and experimental pharmacology & physiology.

[26]  E. Schuuring,et al.  Alternative Splicing of the Actin Binding Domain of Human Cortactin Affects Cell Migration* , 2003, Journal of Biological Chemistry.

[27]  Carsten O. Peterson,et al.  Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. , 2001, Cancer research.

[28]  F. McCormick,et al.  p97/DAP5 is a ribosome‐associated factor that facilitates protein synthesis and cell proliferation by modulating the synthesis of cell cycle proteins , 2006, The EMBO journal.

[29]  J. Stec,et al.  Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  D. Agard,et al.  Estrogen receptor pathways to AP-1 , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[31]  P. McCrea,et al.  Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breastancer , 2000, British Journal of Cancer.

[32]  Javier A Menendez,et al.  Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators? , 2006, Endocrinology.

[33]  Mark Gerstein,et al.  Global Survey of Human T Leukemic Cells by Integrating Proteomics and Transcriptomics Profiling*S , 2007, Molecular & Cellular Proteomics.

[34]  A. Somlyo,et al.  Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. , 2003, Physiological reviews.

[35]  J. Mester,et al.  Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Eng,et al.  Proteomics Analysis of Human Coronary Atherosclerotic Plaque , 2007, Molecular & Cellular Proteomics.

[37]  C. Verschraegen,et al.  Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors , 2004, Clinical & Experimental Metastasis.

[38]  V. Jordan,et al.  The biological role of estrogen receptors alpha and beta in cancer. , 2004, Critical reviews in oncology/hematology.

[39]  C. Haudenschild,et al.  The Role of Tyrosine Phosphorylation of Cortactin in the Locomotion of Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[40]  D. Thomas,et al.  An invasion-related complex of cortactin, paxillin and PKCμ associates with invadopodia at sites of extracellular matrix degradation , 1999, Oncogene.

[41]  A. Cato,et al.  Rapid Actions of Steroid Receptors in Cellular Signaling Pathways , 2002, Science's STKE.

[42]  M. Loda,et al.  Molecular Cloning and Characterization of STAMP1, a Highly Prostate-specific Six Transmembrane Protein that Is Overexpressed in Prostate Cancer* , 2002, The Journal of Biological Chemistry.

[43]  B. Asselain,et al.  Prognostic value of estrogen and progesterone receptors in operable breast cancer: Results of a univariate and multivariate analysis , 1988, Cancer.

[44]  J E Paciga,et al.  AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. , 2001, The American journal of pathology.

[45]  Hyungwon Choi,et al.  Significance Analysis of Spectral Count Data in Label-free Shotgun Proteomics*S , 2008, Molecular & Cellular Proteomics.

[46]  Robert J. Lefkowitz,et al.  β-Arrestin and Mdm2 Mediate IGF-1 Receptor-stimulated ERK Activation and Cell Cycle Progression* , 2007, Journal of Biological Chemistry.

[47]  Nan Guo,et al.  PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways , 2006, Nucleic Acids Res..

[48]  G. Daley,et al.  Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation , 2005, Oncogene.

[49]  R. Daly.  Cortactin signalling and dynamic actin networks. , 2004, The Biochemical journal.

[50]  Eva Enmark,et al.  Ligand-, Cell-, and Estrogen Receptor Subtype (α/β)-dependent Activation at GC-rich (Sp1) Promoter Elements* , 2000, The Journal of Biological Chemistry.

[51]  P. Visca,et al.  Fatty Acid Synthase (Fas) Predictive Strength in Poorly Differentiated Early Breast Carcinomas , 1999, Tumori.

[52]  J. Gustafsson,et al.  Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. , 2000, The Journal of biological chemistry.

[53]  L. Penland,et al.  Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.

[54]  E. Laws,et al.  Selective expression of estrogen receptor alpha and beta isoforms in human pituitary tumors. , 1998, The Journal of clinical endocrinology and metabolism.

[55]  J. Carazo,et al.  GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists , 2007, Genome Biology.

[56]  F. Melsen,et al.  The prognostic value of oncogenic antigen 519 (OA‐519) expression and proliferative activity detected by antibody MIB‐I in node‐negative breast cancer , 1995, The Journal of pathology.

[57]  Michael K. Coleman,et al.  Correlation of relative abundance ratios derived from peptide ion chromatograms and spectrum counting for quantitative proteomic analysis using stable isotope labeling. , 2005, Analytical chemistry.

[58]  Shuh Narumiya,et al.  An essential part for Rho–associated kinase in the transcellular invasion of tumor cells , 1999, Nature Medicine.

[59]  J. Overgaard,et al.  Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum , 2005, International journal of radiation biology.

[60]  B. Alicke,et al.  The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models , 2006, Molecular Cancer Therapeutics.

[61]  E. Petricoin,et al.  Proteomics of human breast ductal carcinoma in situ. , 2002, Cancer research.

[62]  Josephine C. Adams,et al.  The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[63]  Jörg Marienhagen,et al.  GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. , 2009, The American journal of pathology.

[64]  Josephine C. Adams,et al.  Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. , 2003, The American journal of pathology.

[65]  Gregory R. Grant,et al.  Generation of patterns from gene expression data by assigning confidence to differentially expressed genes , 2000, Bioinform..

[66]  M. Rędowicz.  Rho-associated kinase: involvement in the cytoskeleton regulation. , 1999, Archives of biochemistry and biophysics.

[67]  V. Jordan,et al.  The biological role of estrogen receptors α and β in cancer , 2004 .

[68]  R. Spang,et al.  Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[69]  K. Kaibuchi,et al.  Regulation and functions of Rho-associated kinase. , 2000, Experimental cell research.

[70]  Prognostic value of estrogen and progesterone receptors in operable breast cancer: Results of a univariate and multivariate analysis , 1988, Cancer.

[71]  O. Larsson,et al.  Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. , 2007, The Journal of biological chemistry.

[72]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[73]  K. Kaibuchi,et al.  Possible involvement of the inactivation of the Rho-Rho-kinase pathway in oncogenic Ras-induced transformation , 1998, Oncogene.

[74]  James Monypenny,et al.  Rapid Actin Transport During Cell Protrusion , 2003, Science.

[75]  T. Sørlie,et al.  Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms , 2006, BMC Genomics.

[76]  U. Pastorino,et al.  Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer , 2003, British Journal of Cancer.

[77]  J. Eng,et al.  Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues , 2007, Oncogene.

[78]  Mélanie Schmidt,et al.  Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PK , 2010, Journal of Cancer Research and Clinical Oncology.

[79]  K. Resing,et al.  Comparison of Label-free Methods for Quantifying Human Proteins by Shotgun Proteomics*S , 2005, Molecular & Cellular Proteomics.

[80]  P. Leder,et al.  Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. , 2006, Cancer cell.

[81]  J. Yates,et al.  A model for random sampling and estimation of relative protein abundance in shotgun proteomics. , 2004, Analytical chemistry.

[82]  Francisco Tirado,et al.  GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information , 2009, Nucleic Acids Res..

[83]  P. Mullins,et al.  Progesterone and estrogen receptors as prognostic variables in breast cancer. , 1983, Cancer research.

[84]  Steven P Gygi,et al.  A proteomics approach to understanding protein ubiquitination , 2003, Nature Biotechnology.

[85]  Yasuhiro Ito,et al.  S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. , 2008, Current cancer drug targets.

[86]  K. Kumamoto,et al.  Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. , 2007, Cancer research.

[87]  F. Bertucci,et al.  Protein Profiling of Human Breast Tumor Cells Identifies Novel Biomarkers Associated with Molecular Subtypes*S , 2008, Molecular & Cellular Proteomics.

[88]  E. J. Gregory,et al.  Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. , 1977, Cancer research.

[89]  P. McCrea,et al.  Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer , 1999 .